| Dr Milan Sanghavi, MD | |
|
8021 Ritchie Highway, Pasadena, MD 21122-1016 | |
| (410) 590-4616 | |
| (410) 590-4619 |
| Full Name | Dr Milan Sanghavi |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 21 Years |
| Location | 8021 Ritchie Highway, Pasadena, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497967277 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | D0067228 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Neurology Consultants | 1052485471 | 7 |
News Archive
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV.
Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 6 days ago
| Entity Name | Mid-atlantic Neurology Consultants |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821261868 PECOS PAC ID: 1052485471 Enrollment ID: O20080804000207 |
News Archive
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV.
Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 6 days ago
| Entity Name | Neurocare Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134352552 PECOS PAC ID: 3577609346 Enrollment ID: O20091008000135 |
News Archive
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV.
Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Milan Sanghavi, MD 8021 Ritchie Highway, Pasadena, MD 21122-1016 Ph: (410) 590-4616 | Dr Milan Sanghavi, MD 8021 Ritchie Highway, Pasadena, MD 21122-1016 Ph: (410) 590-4616 |
News Archive
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV.
Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 6 days ago
Wendie Malkinski, NURSE PRACTITIONER Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 232 Dale Rd, Pasadena, MD 21122 Phone: 443-668-4300 |